Tofacitinib experience in patients with enteropathic arthritis.

Abstract

Background/aim: The JAK-STAT pathway is involved in the pathogenesis of both the inflammatory bowel disease (IBD) and spondyloarthropathy group of diseases. The purpose of this study was to evaluate the effectiveness of tofacitinib, a Janus kinase inhibitor, in the treatment of enteropathic arthritis (EA). Materials & methods: The study included seven patients, four from the authors' follow-up and three from the literature. All cases were recorded for demographic characteristics, comorbidities, IBD and EA symptoms, medical treatments and changes in clinical and laboratory results with treatment. Results & conclusion: Clinical and laboratory remission in terms of IBD and EA was achieved in three patients after tofacitinib treatment. For both spondyloarthritis spectrum diseases and IBD, tofacitinib may be an appropriate choice, as its efficacy has been shown in both conditions.

• Authors: Pınar Akyüz Dağlı, Abdulsamet Erden, Serdar Can Güven, Berkan Armağan, Öykü Tayfur Yürekli, Yasemin Özderin Özin, Ahmet Omma, Orhan Küçükşahin
• Journal: Immunotherapy (Immunotherapy) Vol. 15 Issue 8 Pg. 619-626 (06 2023) ISSN: 1750-7448 [Electronic] England
• PMID: 37009645 (Publication Type: Journal Article, Review)

Chemical References

• tofacitinib
• Janus Kinases
• Protein Kinase Inhibitors
• STAT Transcription Factors
• Pyrroles

Topics

• Humans
• Janus Kinases
• Protein Kinase Inhibitors (therapeutic use)
• Signal Transduction
• STAT Transcription Factors (metabolism)
• Inflammatory Bowel Diseases (drug therapy)
• Gastrointestinal Diseases
• Spondylarthritis (drug therapy)
• Pyrroles (therapeutic use)
• Colitis, Ulcerative (drug therapy)